August 14, 2024, New Delhi: As India celebrates the 78th Independence Day, Panacea Biotec Limited and Indian Council of Medical Research are proud to share that with the approval of the Drugs Controller General of India (DCGI), we have started the Phase III clinical trial of our tetravalent dengue candidate vaccine, DengiALL in India. The clinical trial will be conducted at 19 sites with 10,335 participants across India.
The development of DengiALL was initiated at Panacea Biotec in 2006 with the licensing and transfer of novel attenuated tetravalent strains of dengue virus between Panacea Biotec and National Institutes of Health, USA. Panacea Biotec has undertaken Phase I/II clinical trials in the Indian population with 3 years of safety follow-up completed in 2020. Subsequently, Panacea Biotec and ICMR entered into an MOU in March 2022 for Phase III clinical trials in India.
To read the full press release, click HERE
